Business Context and Reporting Period
This Form 8-K is filed by First Light Acquisition Group, Inc. (not Calidi Biotherapeutics, Inc.) on December 15, 2022. The registrant is a Special Purpose Acquisition Company (SPAC) incorporated in Delaware, with securities trading on the New York Stock Exchange under the symbols FLAGU, FLAG, and FLAGW.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial figure disclosed relates to the extension of the initial business combination deadline:
- Trust Account Funding: $415,626 was deposited into the Company's trust account in connection with the extension.
Revenue, margins, debt, and liquidity metrics are not reported in this document.
Material Changes
The primary material event reported is the approval by the Board of Directors on December 14, 2022, to extend the deadline for completing the Company's initial business combination:
- Previous Deadline: December 14, 2022
- New Deadline: March 14, 2023
Outlook, Risks, and Management Commentary
Management announced the extension via a press release on December 15, 2022, which is incorporated as Exhibit 99.1. The filing does not contain specific forward-looking guidance, risk factors, or commentary regarding the status of potential target acquisitions beyond the extension of the timeline.
Investor Verification Checklist
- Verify the identity of the registrant: This filing is for First Light Acquisition Group, Inc., not Calidi Biotherapeutics, Inc.
- Confirm the new deadline for the initial business combination is March 14, 2023.
- Review the attached press release (Exhibit 99.1) for details on the terms of the extension and any associated shareholder rights.
- Note that no financial performance data is available in this specific 8-K filing.